化學名

ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate

簡稱

Retigabine

別名

D-23129, Ezogabine, D23129, D 23129

中文名

瑞替加濱

化學式

C₁₆H₁₈FN₃O₂

分子量

303.33

CAS號

150812-12-7

純度

98%

溶劑/溶解度

Water<1mg/ml; DMSO4mg/ml; Ethanol<1mg/ml

溶液配制

5mg加入1.65ml DMSO，或者每3.03mg加入1ml DMSO，配制成10mM溶液。SF8993-10mM用DMSO配制。

產(chǎn)品描述

Retigabine (Ezogabine; D23129) is a Kv7.2-7.5 (KCNQ2-5) neuronal potassium channel opener witrh anticonvulsant activity.

信號通路

Transmembrane Transporters

靶點

Kv7.2-7.5

－

－

－

－

IC50

－

－

－

－

－

體外研究

Retigabine (D-23129) is a novel antiepileptic compound with broad spectrum and potent anticonvulsant properties, both in vitro and in vivo. The compound was shown to activate a K⁺ current in neuronal cells. The pharmacology of the induced current displays concordance with the published pharmacology of the M-channel, which recently was correlated to the KCNQ2/3 K⁺ channel heteromultimere. Retigabine is a novel anticonvulsant with an unknown mechanism of action. Application of 10μM retigabine to oocytes expressing the KCNQ2/3 heteromeric channel shifted both the activation threshold and voltage for half-activation by approximately 20mV in the hyperpolarizing direction, leading to an increase in current amplitude at test potentials between 80mV and +20mV. Retigabine also had a marked effect on KCNQ current kinetics, increasing the rate of channel activation but slowing deactivation at a given test potential. Retigabine shifted the voltage dependence of channel activation with an EC50value of 1.6±0.3μM (slope factor was 1.2±0.1, n=4 to 5 cells per concentration). Retigabine (0.1 to 10μM) also slowed the rate of channel deactivation, predominantly by increasing the contribution of a slowly deactivating tail current component. Administration of centrally acting M-channel opener retigabine (2.5 and 7.5mg/kg) can dose-dependently raise the head withdrawal threshold of mechanical allodynia, and this analgesic effect can be reversed by the specific KCNQ channel blocker XE991 (3mg/kg). Food intake was increased significantly by the administration of retigabine (2.5 and 7.5mg/kg), and this effect was reversed by XE991 (3mg/kg). Furthermore, intracerebralventricular injection of retigabine further confirmed the analgesic effect of central retigabine on inflammatory TMJ. Retigabine exerted both antiepileptogenic and antiictogenic effects under conditions of rapid kindling model.

體內(nèi)研究

N/A

臨床實驗

N/A

特征

N/A

酶活性檢測實驗

方法

N/A

細胞實驗

細胞系

N/A

濃度

N/A

處理時間

N/A

方法

N/A

動物實驗

動物模型

N/A

配制

N/A

劑量

N/A

給藥方式

N/A

產(chǎn)品編號

產(chǎn)品名稱

包裝

SF8993-10mM

Retigabine (Potassium Channel開放劑)

10mM×0.2ml

SF8993-5mg

Retigabine (Potassium Channel開放劑)

5mg

SF8993-25mg

Retigabine (Potassium Channel開放劑)

25mg

—

說明書

1份